Glenmark Pharmaceuticals Ltd

- The transcript from Glenmark Pharmaceuticals' Q4 FY '25 earnings call does not explicitly provide detailed figures on the current or expected order book or pending orders. - However, there is strong emphasis on upcoming launches and market opportunities: - Multiple filings in the U.S. in Q2 FY'26 including 3 MDI (metered-dose inhaler) filings and 2-3 nasal sprays. - Launch of BeiGene in-licensed assets (tislelizumab and a BTK product) with significant market potential in India ($200 million+ PD-1/PD-L1 market). - Continued growth in India with RYALTRIS expected to cross $100 million in sales for FY '26. - Discussions indicate ongoing advanced talks and expected quick closure on the ISB 2001 licensing deal, projected to be transformational. - Overall, the company demonstrates a healthy pipeline with multiple launches and licensing deals expected to drive future order flow and revenue growth.

- Glenmark Pharmaceuticals currently has net debt of around INR 489 crores as of March 2025. - There is no explicit mention of any planned new fundraising through debt or equity in the provided transcript. - The company has indicated that post-closing a licensing deal with IGI (Innovative Genomics Institute), IGI will be self-sustaining for at least the next 3-4 years without requiring additional investment from Glenmark. - Glenmark expects that the licensing deal will cover IGI's expenditure of about $70 million per year. - No specific plans for raising new debt or equity are mentioned; the focus is on operational cash generation guided at INR 300 to 400 crores and funding innovation through licensing deals rather than new fundraising rounds.

- Monroe plant: $150 million investment remains, mainly in injectable lines and utilities. Goal is to get the plant operational with good filings expected (Page 17). - IGI investment: Approximately $70 million annual investment expected over next 3 years, covering clinical trial costs and R&D. After a licensing deal, IGI is expected to be self-sustaining with no further investments needed from Glenmark (Pages 10, 7, 6). - Asset additions in FY '25: Total INR 698 crores added; INR 309 crores in Q4 alone (INR 226 crores tangible, INR 84 crores intangible) (Page 6). - Planning to transfer some CMC activities to contract development and manufacturing organizations for cost efficiency (Page 15). - No large expansions in sales force currently planned, existing workforce to drive growth (Page 14).

- FY '26 revenue growth guidance is 10% to 12%. - Strong growth expected in ROW (Rest of World) and Europe, with ROW growing 10+% in FY '25 and expected to accelerate. - Significant launches in India planned, including BeiGene launches (tislelizumab and zanubrutinib) in early Q1 FY '26. - U.S. launches in H2 FY '26, including Flovent approval expected end of Q2 and nasal spray launch in H2. - RYALTRIS sales expected to cross $100 million in FY '26, up from $80 million in FY '25. - India business growth expected to strengthen after bottoming out in diabetes; other segments like cardio, derm, and respiratory growing well. - IGI innovation spend around $70 million annually for next 3 years, to be self-funded post-licensing deal. - EBITDA margin guidance of 19% to 20%, supported by new product launches and R&D efficiencies.

- Glenmark Pharmaceuticals is targeting a revenue growth of 10% to 12% for FY '26. - EBITDA margin guidance is set between 19% to 20%, driven by new product launches such as RYALTRIS and two major U.S. launches in H2 FY '26. - Free cash flow generation is expected to be between INR 300 crores to INR 400 crores, post interest and dividend payments. - Margin improvement is supported by operational efficiencies, controlled R&D spend (~6-7% of sales), and resolution of manufacturing plant issues. - Innovation entity IGI’s $70 million annual investment is expected to be self-sustaining post a licensing deal, which will further improve consolidated margins. - Market expansion in India, Europe, and Rest of World (ROW) with growth in derm, cardio, respiratory, and oncology pipelines. - Overall EPS and profit growth expected to benefit from margin expansion and stable revenue growth, with management to provide more granularity in upcoming analyst meets.